Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 1999

View Archived Issues

Ortec requests FDA permission to initiate CCS trial for diabetic ulcer therapy

Company Profile: Verne Mendel Medical

Apligraf skin construct speeds healing of diabetic foot ulcers

Topical foscarnet for aciclovir-unresponsive HSV lesions in AIDS patients

SciClone licenses new class of immunomodulators from University of California

Searle pays milestone to Epimmune for anticancer candidate

Glaxo Wellcome proposes to discontinue Wellferon

Interneuron completes patient enrollment in ECCO 2000

Muse approved in Spain

Diatide awarded patent covering somatostatin analogues for tumor diagnosis and therapy

Boston Life Sciences reviews progress for first half of 1999

NDA for subcutaneous Repronex approved by FDA

New IGT compound shows promise in stroke therapy

AstraZeneca terminates two development agreements during first half of 1999

Preclinical and mechanism of action studies support efficacy of the NHE-1 inhibitor cariporide

Anti-RSV agents reported in patent literature by ViroPharma

Novel emopamil binding site inhibitors synthesized and evaluated at AstraZeneca

Novel BK channel modulators for stroke reported by Bristol-Myers Squibb

AHP investigates oxazole derivatives with potential in treating various CNS disorders

HRT may slow periodontal disease progression

Celecoxib NDA receives priority review designation for FAP

ME-3230, an orally active prodrug of a potent gpIIb/IIIa antagonist

FDA requests modifications to Bexxar BLA

ETA antagonist TA-0201 protects against deleterious effects of MI in dogs

New treatment for urinary incontinence in the Recordati pipeline

DuPont team presents new cdk inhibitors at ACS meeting

5-ht6 receptor function under study at SmithKline Beecham

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...